Pages that link to "Q36791243"

The following pages link to Are we misunderstanding beta-blockers (Q36791243):

Displaying 28 items.

• Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine (Q33902610) (← links)
• Pharmacological and non-pharmacological interventions to influence adipose tissue function. (Q34576535) (← links)
• Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling (Q34837191) (← links)
• A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension (Q34988304) (← links)
• Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure (Q35117742) (← links)
• A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling (Q36082162) (← links)
• Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. (Q36318886) (← links)
• Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. (Q36936400) (← links)
• Managing hypertension in the elderly in light of the changes during aging (Q37229310) (← links)
• Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis (Q37288326) (← links)
• Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists (Q37629384) (← links)
• Safety of perioperative β-blocker use: how do β-blockers compare in terms of side effects? (Q37830055) (← links)
• The role of β-blockers in the management of hypertension: An Asian perspective (Q37853549) (← links)
• Lipid effects of antihypertensive medications (Q37950846) (← links)
• Cardio‐Selective Beta‐Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity (Q37978886) (← links)
• The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure (Q38012491) (← links)
• Is exercise training beneficial for heart failure patients taking β-adrenergic blockers? A systematic review and meta-analysis (Q38041679) (← links)
• Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure (Q38469887) (← links)
• The Real Role of β-Blockers in Daily Cardiovascular Therapy (Q39208428) (← links)
• Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts (Q41906203) (← links)
• Perioperative evaluation of cardiac surgical risk: particularities in the emergency surgery - from the guidelines to the clinical practice (Q42028649) (← links)
• Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. (Q42191909) (← links)
• Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. (Q42201896) (← links)
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery (Q43284567) (← links)
• One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study (Q43296475) (← links)
• The effect of atenolol on NT-proBNP and troponin in asymptomatic cats with severe left ventricular hypertrophy because of hypertrophic cardiomyopathy: a pilot study. (Q45973995) (← links)
• Ivabradine has a neutral effect on mortality in randomized controlled trials (Q49249173) (← links)
• Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca (Q57245270) (← links)